Stock KROS KEROS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Keros Therapeutics, Inc.

Equities

KROS

US4923271013

Market Closed - Nasdaq
Other stock markets
 21:00:00 13/05/2024 BST 		5-day change 1st Jan Change
54 USD -0.50% Intraday chart for Keros Therapeutics, Inc. -10.39% +35.81%
05-08 Earnings Flash (KROS) KEROS THERAPEUTICS Reports Q1 Revenue $83,000 MT
05-08 Keros Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
AQ
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes
AQ
Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference
AQ
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
AQ
Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress
AQ
Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock
AQ
Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
AQ
Keros Therapeutics Announces Proposed Public Offering of Common Stock
AQ
Keros Therapeutics to Develop KER-065 for the Treatment of Obesity
AQ
Keros Therapeutics Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition
AQ
Keros Therapeutics to Present at Upcoming Healthcare Conferences
AQ
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2023 Financial Results
AQ
Keros Therapeutics to Present at the 65th American Society of Hematology Annual Meeting and Exposition
AQ
Keros Therapeutics Presents Preclinical Data from its KER-065 Program at the 28th International Annual Congress of the World Muscle Society
AQ
Keros Therapeutics to Present at Upcoming Healthcare Conferences
AQ
Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results
AQ
Keros Therapeutics : KER-012 Investor Call Deck August 2023
PU
Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension
AQ
Keros Therapeutics Announces Update to Participation at the Goldman Sachs 44th Annual Global Healthcare Conference
AQ
Keros Therapeutics : Hematology Franchise Investor Call Presentation
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KROS Stock
  4. News Keros Therapeutics, Inc.
  5. Press Releases